Tools

LEADER 02827cam a2200541 a 4500

001 ocm41321493;

003 OCoLC;

005 20040429091642.0;

006 m d f ;

007 cr unu||||||||;

008 990507s1999 mdu o f000 0 eng c;

042 a| pcc;

049 a| ERE#;

074 a| 0491-B-31 (online);

086 0 a| HE 20.6524:4/SUM.;

245 00 a| Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer.;

256 a| Electronic data.;

260 a| [Rockville, Md. :b| U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research,c| 1999];

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

490 1 a| Evidence report/technology assessment. Summary ;v| no. 4;

490 1 a| AHCPR publication ;v| no. 99-E011;

538 a| Mode of access: Internet from the AHCPR web site. Address as of 4/29/04: http://www.ahrq.gov/clinic/epcsums/prossumm.htm; current access available via PURL.;

500 a| Title from title screen (viewed on Apr. 29, 2004).;

500 a| "January 1999.";

500 a| "The full evidence report from which this summary was taken was prepared by the Evaluation Technology Center, an AHCPR Evidence-based Practice Center of the Blue Cross and Blue Shield Association, Chicago, Illinois, under contract no. 290-97-0015.";

500 a| GPO Cataloging Record Distribution Program (CRDP).;

650 0 a| Prostatex| Cancerx| Hormone therapy.=| ^A1195498;

650 0 a| Antiandrogensx| Therapeutic use.=| ^A825164;

650 2 a| Androgen Antagonistsx| therapeutic use.=| ^A936315;

650 2 a| Cost-Benefit Analysis.=| ^A919295;

650 2 a| Gonadorelinx| antagonists & inhibitors.?| UNAUTHORIZED;

650 2 a| Outcome Assessment, Health Care=| ^A926961;

650 2 a| Prostatic Neoplasmsx| drug therapy.=| ^A922044;

650 2 a| Randomized Controlled Trials.?| UNAUTHORIZED;

710 1 a| United States.b| Agency for Health Care Policy and Research.=| ^A331264;

710 2 a| Blue Cross and Blue Shield Association.b| Technology Evaluation Center.=| ^A571087;

776 1 t| Relative effectiveness and cost-effectiveness of methods of andogen suppression in the treatment of advanced prostatic cancerh| [6] p.w| (OCoLC)43871810;

830 0 a| AHCPR pub. ;v| no. 99-E 011.=| ^A467686;

830 0 a| Evidence report/technology assessment.p| Summaryv| no. 4.=| ^A578517;

856 40 u| https://purl.fdlp.gov/GPO/LPS48106;

949 a| Click on web addressw| asish| joyner94;

096 a| WJ 752 .R382 1999;

596 a| 1;

998 a| 961053;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| MQ1696740d| 8/7/2007l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 6/7/2004x| EDOCUMENTz| JERESOURCEo| .STAFF. 0;

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer.

Other author	United States. Agency for Health Care Policy and Research.
Other author	Blue Cross and Blue Shield Association. Technology Evaluation Center.
Format	Electronic
Publication Info	[Rockville, Md. : U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1999]
Supplemental Content	https://purl.fdlp.gov/GPO/LPS48106
Subjects	Prostate--Cancer. --Hormone therapy. Antiandrogens--Therapeutic use. Androgen Antagonists--therapeutic use. Cost-Benefit Analysis. Gonadorelin--antagonists & inhibitors. Outcome Assessment, Health Care Prostatic Neoplasms--drug therapy. Randomized Controlled Trials.

Data characteristics	Electronic data.
Series	Evidence report/technology assessment. Summary ; no. 4 AHCPR publication ; no. 99-E011 AHCPR pub. ; no. 99-E 011. ^A467686 Evidence report/technology assessment. Summary no. 4. ^A578517
General note	Title from title screen (viewed on Apr. 29, 2004).
General note	"January 1999."
General note	"The full evidence report from which this summary was taken was prepared by the Evaluation Technology Center, an AHCPR Evidence-based Practice Center of the Blue Cross and Blue Shield Association, Chicago, Illinois, under contract no. 290-97-0015."
General note	GPO Cataloging Record Distribution Program (CRDP).
Technical details	Mode of access: Internet from the AHCPR web site. Address as of 4/29/04: http://www.ahrq.gov/clinic/epcsums/prossumm.htm; current access available via PURL.
GPO item number	0491-B-31 (online)
Govt. docs number	HE 20.6524:4/SUM.

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer.

Click here for more information about this title

Availability